Investigating the role of Diamine Oxidase in pregnancy complications

Diamine Oxidase and Adverse Pregnancy Outcomes

Observational Hospital Universitari Vall d'Hebron Research Institute · NCT06281366

This study is trying to see if measuring a substance called Diamine Oxidase in women at high risk for preeclampsia during early pregnancy can help us understand and improve their chances of having a healthy baby.

Quick facts

Study typeObservational
Enrollment75 (estimated)
Ages18 Years and up
SexFemale
SponsorHospital Universitari Vall d'Hebron Research Institute Academic / other
Locations1 site (Barcelona)
Trial IDNCT06281366 on ClinicalTrials.gov

What this trial studies

This observational study examines the relationship between Diamine Oxidase (DAO) activity and adverse pregnancy outcomes, particularly in women identified as high-risk for preeclampsia during their first-trimester screening. It aims to understand how reduced DAO activity may correlate with complications such as miscarriage, fetal demise, preeclampsia, low birthweight, and preterm birth. The study will involve women with single pregnancies who are between 11 and 16 weeks of gestation and have a high-risk screening result for preeclampsia. By analyzing DAO levels, the study seeks to provide insights into potential interventions for improving pregnancy outcomes.

Who should consider this trial

Good fit: Ideal candidates for this study are women aged 18 and older with a single pregnancy who have been identified as high-risk for preeclampsia during their first-trimester screening.

Not a fit: Patients with fetal malformations, fetal death, or maternal digestive inflammatory diseases may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to better screening and management strategies for high-risk pregnancies, potentially reducing the incidence of severe complications.

How similar studies have performed: While the specific approach of examining DAO activity in this context may be novel, previous studies have indicated a link between DAO levels and pregnancy complications, suggesting potential for success.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Single pregnancy
* Maternal age ≥18
* High risk (≥1/50) in the first-trimester screening for preeclampsia
* Gestational age between 11+0 and 16+6 weeks of gestation

Exclusion Criteria:

* Fetal malformation
* Fetal death
* Maternal digestive inflammatory disease or intolerance
* Refusal to give informed consent

Where this trial is running

Barcelona

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Pregnancy ComplicationsPreeclampsiaPPROMpreterm birthFetal deathLow birthweight
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.